We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.
In cooperation with Association of Corporate Counsel
  Request new password

Search results

Order by most recent / most popular / relevance

Results: 1-10 of 10

Aastrom biosciences announces financing deal to advance CVD treatments

  • Shook Hardy & Bacon LLP
  • -
  • USA
  • -
  • March 29 2012

Aastrom Biosciences, an Ann Arbor, Michigan-based biotech startup, has announced a $40-million financing deal with large institutional investor Eastern Capital Limited

Biotech set to raise $86 million in IPO to support cancer and IEM products

  • Shook Hardy & Bacon LLP
  • -
  • USA
  • -
  • June 20 2013

Agios Pharmaceuticals, Inc. has filed a registration statement with the U.S. Securities and Exchange Commission indicating its intent to raise up to

Putative class alleges pharma statements about new drug violated securities laws

  • Shook Hardy & Bacon LLP
  • -
  • USA
  • -
  • May 16 2013

Aveo Pharmaceuticals, Inc. and several of its executives have been targeted in a securities class action filed in a federal court in Massachusetts

Eighth Circuit allows investor suit to proceed against pharmaceutical co

  • Shook Hardy & Bacon LLP
  • -
  • USA
  • -
  • June 7 2012

The Eighth Circuit Court of Appeals has determined that investors alleging securities fraud against a pharmaceutical company which claimed in its Securities and Exchange Commission filings that it was in material compliance with Food and Drug Administration (FDA) regulations sufficiently pleaded that the claims were false or misleading

Two Boston-area biotechs set to raise $146 million in IPOs

  • Shook Hardy & Bacon LLP
  • -
  • USA
  • -
  • March 21 2013

According to a news source, Enanta Pharmaceuticals, Inc. and Tetraphase Pharmaceuticals, Inc. were poised to raise a combined total of $146 million

PROLOR Biotech to raise $75 million for clinical trials on growth hormones

  • Shook Hardy & Bacon LLP
  • -
  • Israel, USA
  • -
  • April 19 2012

In an April 6, 2012, filing with the U.S. Securities and Exchange Commission, Israel-based PROLOR Biotech, Inc. has registered the sale of common stock on the American Stock Exchange in an amount not to exceed $75 million

IPOs sluggish in 2011 on disappointing returns

  • Shook Hardy & Bacon LLP
  • -
  • USA
  • -
  • January 19 2012

Biotech initial public offerings (IPOs) tracked the market as a whole in 2011, with fewer filed and returns in the negative column

$9.2 million in equity reported to SEC by stem-cell treatment corp.

  • Shook Hardy & Bacon LLP
  • -
  • USA
  • -
  • August 30 2012

In a regulatory filing with the U.S. Securities and Exchange Commission (SEC), Fate Therapeutics, Inc. has reported that it raised $9.2 million in equity

Cancer genetics IPO raises $6.9 million

  • Shook Hardy & Bacon LLP
  • -
  • USA
  • -
  • April 18 2013

Rutherford, New Jersey-based Cancer Genetics, Inc., an early-stage diagnostics company that develops genomic-based, oncology tests and services, has

PolyMedix expects to raise $25 million for antibiotic development

  • Shook Hardy & Bacon LLP
  • -
  • USA
  • -
  • March 21 2013

PolyMedix, Inc. stockholders have overwhelmingly approved a reverse stock split of the company's common stock at a ratio of up to fifty-for-one